Status:
COMPLETED
Is Augmentation of PORH by Rosuvastatin Adenosine-receptor Mediated?
Lead Sponsor:
Radboud University Medical Center
Conditions:
Atherosclerosis
Cardiovascular Disease
Eligibility:
All Genders
18-50 years
Phase:
PHASE4
Brief Summary
Rationale: Statins form a class of drugs that is widely prescribed for hypercholesterolaemia, specifically to reduce the risk on atherosclerosis by lowering LDL-cholesterol. Next to the effect for wh...
Eligibility Criteria
Inclusion
- Age 18-50
- Written informed consent
Exclusion
- History of any cardiovascular disease
- Hypertension (in supine position: systole \>140 mmHg, diastole \>90 mmHg)
- Diabetes Mellitus (fasting glucose \>7.0 mmol/L or random glucose \>11.0 mmol/L)
- Hyperlipidemia (fasting total cholesterol \>5.5 mmol/L or random cholesterol \>6.5 mmol/L)
- Alanine amino transferase \>90 U/L
- Creatin kinase \>440 U/L
- Raised rhabdomyolysis risk (GFR \<80 ml/min and/or overt clinical signs of hypothyroidism and/or myopathy in family history
- Alcohol abuse
- Concommitant chronic use of medication
- Participation to any drug-investigation during the previous 60 days as checked with VIP check
Key Trial Info
Start Date :
March 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 1 2009
Estimated Enrollment :
8 Patients enrolled
Trial Details
Trial ID
NCT00851175
Start Date
March 1 2009
End Date
September 1 2009
Last Update
October 1 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
RUNMC
Nijmegen, Netherlands, 6525 GA